Advanced Enzyme Technologies Limited announced a significant board meeting outcome on August 08, 2026. Key decisions include the approval of an un-audited financial results for the quarter ended June 30, 2026, and a share buyback program of equity shares up to ₹500 per share, with an aggregate amount not exceeding ₹697 million. The company also approved the acquisition of the remaining stake in JC Biotech Private Limited, aiming to make it a wholly-owned subsidiary, and an infusion of funds into Advanced Nutrazyme Private Limited.
Board Approves Key Strategic Initiatives
At its meeting held on August 08, 2026, the Board of Directors of Advanced Enzyme Technologies Limited transacted significant business, including the approval of the un-audited financial results for the quarter ended June 30, 2026, alongside a Limited Review Report. The board also greenlit a buyback of the Company’s fully paid-up equity shares.
Share Buyback Program Details
The buyback will be conducted at a price not exceeding ₹500 per equity share, for an aggregate amount not exceeding ₹697,000,000 (₹697 million). The buyback will be carried out through the ‘Open Market’ route via the stock exchange mechanism, excluding shares held by Promoters and persons in control. The indicative maximum number of equity shares to be bought back is 1,394,000 shares, representing approximately 1.24% of the existing paid-up equity capital.
Strategic Acquisitions and Investments
In addition to the buyback, the Board approved the acquisition of the remaining stake of 4.28% in JC Biotech Private Limited (JCB). This move is intended to make JCB a wholly owned subsidiary, optimizing synergies across consolidated business operations. Furthermore, the company approved the infusion of additional funds not exceeding ₹20 million into Advanced Nutrazyme Private Limited (ANPL) through equity investment or inter-corporate deposit to support its business and general corporate purposes.
Source: BSE
